<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243125</url>
  </required_header>
  <id_info>
    <org_study_id>CL1001</org_study_id>
    <nct_id>NCT01243125</nct_id>
  </id_info>
  <brief_title>Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation</brief_title>
  <official_title>A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaBay Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaBay Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NVC-422 is a topical, non-antibiotic, fast-acting, broad-spectrum anti-microbial, which
      exhibits the potential to prevent the growth of urinary pathogens, including Proteus and
      others.

      The use of a catheter irrigation solution that can prevent biofilm formation and encrustation
      leading to blockage may keep the catheter patent longer, resulting in fewer catheter changes,
      potentially lower incidence of UTIs, and better patient quality of life.

      The study population will include male and female spinal cord injury (SCI) and other
      neurogenic bladder patients with chronic indwelling transurethral urinary catheters who have
      a recent repeated history of urinary catheter encrustation and/or blockage.

      Subjects will receive two treatment regimens: one treatment regimen with NVC-422 sterile
      irrigation solution and one treatment regimen with sterile saline irrigation solution. Each
      treatment regimen will consist of a total of 8 treatments, with a washout period between
      treatment regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter patency following treatment</measure>
    <time_frame>26 days</time_frame>
    <description>Cross sectional area (percent of open area that is not encrusted) will be determined at pre-selected loci on the catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of catheter blockage requiring early removal</measure>
    <time_frame>26 days</time_frame>
    <description>Catheters removed prior to completion of treatment regimen will be assessed for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biofilm of catheter</measure>
    <time_frame>26 days</time_frame>
    <description>Qualitative and quantitative assessment of biofilm of catheter will be determined for all catheters removed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of encrustation of catheter</measure>
    <time_frame>26 days</time_frame>
    <description>Qualitative and quantitative assessment of encrustation of catheter will be determined for all catheters removed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Urinary Catheter Blockage and Encrustation</condition>
  <arm_group>
    <arm_group_label>NVC-422</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVC-422, 0.2%</intervention_name>
    <description>0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period</description>
    <arm_group_label>NVC-422</arm_group_label>
    <other_name>N,N-dichloro-2,2-dimethyltaurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile normal saline, 0.9%</intervention_name>
    <description>Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>0.9% Sodium chloride for injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spinal Cord Injury (SCI) or other neurogenic bladder patient requiring a chronic
             indwelling urinary catheter with history of catheter blockage and/or encrustation

          -  Screening within 30 days of first treatment

        Exclusion Criteria:

          -  Systemic antibiotics within 7 days of first treatment

          -  Investigational drug or device within 30 days of enrollment

          -  Current infection that requires treatment with systemic antibiotics

          -  Recent history of significant autonomic dysreflexia (requiring intervention or
             treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth D. Krantz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NovaBay Pharmaceuticals / kkrantz@novabaypharma.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Amigos Research and Education Institute (LAREI)</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialists in Urology</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kessler Institute for Rehabilitation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire Veterans Affairs Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Medical Research</name>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <disposition_first_submitted>August 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 7, 2014</disposition_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blockage</keyword>
  <keyword>Encrustation</keyword>
  <keyword>Catheter</keyword>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>SCI</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

